Ratings RadNet, Inc.

Equities

RDNT

US7504911022

Real-time Estimate Cboe BZX Other stock markets 02:39:47 2024-04-18 pm EDT			5-day change	1st Jan Change
47.54 ^USD	-0.54%		-3.03%	+37.30%

Apr. 11	RadNet Prices, Upsizes Term Loan, Revolving Credit Facility Refinancing Transaction	MT
Apr. 11	RadNet, Inc. Announces Pricing and Upsizing of its Previously Announced Term Loan and Revolving Credit Facility Refinancing Transaction	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts covering this company mostly recommend stock overweighting or purchase.
Over the past four months, analysts' average price target has been revised upwards significantly.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

Low profitability weakens the company.
With an expected P/E ratio at 91.92 and 62.89 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The valuation of the company is particularly high given the cash flows generated by its activity.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
RADNET, INC.	+37.30%	3.52B		C+
SONIC HEALTHCARE LIMITED	-19.23%	8.01B		B+
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-26.72%	2.98B		B-
SYNLAB AG	-7.36%	2.48B		-
DR. LAL PATHLABS LIMITED	-12.92%	2.31B		B-
NEOGENOMICS, INC.	-14.31%	1.75B		C-
FLEURY S.A.	-23.23%	1.45B		A-
DIAN DIAGNOSTICS GROUP CO.,LTD.	-39.19%	1.27B		C+
ADICON HOLDINGS LIMITED	-7.98%	1.08B	-	-
METROPOLIS HEALTHCARE LIMITED	+3.67%	1.07B		B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes